A
Alumis Inc. (ALMS)
NMS – Real Time Price. Currency in USD
23.51
-0.15 (-0.63%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
23.51
-0.15 (-0.63%)
At close: May 12, 2026, 4:00 PM EDT
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer & Head of Research and Development |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer |
| Mr. Kolbot By Ph.D. | Senior VP & Head of Technical Operations |
| Mr. Mark Bradley | Chief Development Officer |
| Mr. Martin Babler Ph.D. | President, CEO & Chairman |
| Mr. Philip Nunn Ph.D. | Senior VP of Pharmacology & Project Team Leader |
| Mr. Roy C. Hardiman J.D. | Chief Business & Strategy Officer |
| Ms. Claire Langrish Ph.D. | Senior VP & Head of Immunology and Translational Science |
| Ms. Sanam Pangali J.D. | Chief Legal Officer & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-03-30 | 8-K | tm269978d1_8k.htm |
| 2026-03-19 | 10-K | alms-20251231x10k.htm |
| 2026-01-30 | S-8 | tm263983d1_s8.htm |
| 2026-01-09 | 8-K | tm262561d1_8k.htm |
| 2026-01-02 | 8-K | tm2534587d2_8k.htm |
| 2025-11-13 | 10-Q | alms-20250930x10q.htm |
| 2025-09-03 | 8-K | tm2525079d1_8k.htm |
| 2025-08-15 | CORRESP | filename1.htm |
| 2025-08-13 | 10-Q | alms-20250630x10q.htm |
| 2025-08-04 | 8-K | tm2521941d1_8k.htm |